Optimization of Conditions for Human Bacterial Preparation for Biological Correction of Intestinal Microflora

Article Sidebar

pdf (Русский) pdf html (Русский) html
Published: Jun 29, 2021
DOI: https://doi.org/10.18097/BMCRM00151
Keywords:
fecal microbiota transplantation; lyophilized oral capsules; lyoprotectants; short-chain fatty acids

Main Article Content

E.A. Sorokina
Federal Scientific and Clinical Center for Physico-Chemical Medicine, 1a Malaya Pirogovskaya str., Moscow, 119435 Russia
E.S. Zhgun
Federal Scientific and Clinical Center for Physico-Chemical Medicine, 1a Malaya Pirogovskaya str., Moscow, 119435 Russia
Yu.V. Kislun
Federal Scientific and Clinical Center for Physico-Chemical Medicine, 1a Malaya Pirogovskaya str., Moscow, 119435 Russia
E.A. Denisova
Federal Scientific and Clinical Center for Physico-Chemical Medicine, 1a Malaya Pirogovskaya str., Moscow, 119435 Russia
Yu.A. Bespyatykh
Federal Scientific and Clinical Center for Physico-Chemical Medicine, 1a Malaya Pirogovskaya str., Moscow, 119435 Russia
E.N. Ilina
Federal Scientific and Clinical Center for Physico-Chemical Medicine, 1a Malaya Pirogovskaya str., Moscow, 119435 Russia

Abstract

Fecal microbiota transplantation (FMT) is now considered as an effective tool for the treatment of various GI pathologies. Fecal preparations are delivered both through the lower GIT (enema, colonoscopy) and upper (endoscopy, capsules). A common disadvantage of instrumental methods of administration is their high invasiveness associated with the risk of intestinal perforation and the use of anesthesia. Oral capsules are minimally invasive, comfortable and more aesthetic, so this method of drug delivery is gaining popularity. The main issue with the use of frozen feces (including the lyophilisate used in capsules) is its efficiency compared to the original material. During lyophilization, cells are exposed to stress factors such as low temperatures, water crystallization, osmotic stress, changes in pH, and dehydration. To reduce the likelihood of cell damage during lyophilization, protective media (lyo-protectants) are used. In this work sucrose, gelatin, and their combinations have been used as lyoprotectors. To estimate the number of microorganisms, a bacteriological study was carried out. The number of Bifidobacteria, Lactobacilli, and the total number of E.coli and Enterobacteriaceae was estimated. It was found that the lyophilized stool sample containing 10% sucrose as a protective medium had the highest number of viable cells. Also, the physical properties of the lyophilisate (its flowability) are convenient for preparing capsulated form. The molar ratios of short chain fatty acids (SCFAs) in the original fecal samples and lyophilisates were studied by gas chromatography. The molar ratios of major SCFAs (acetate, propionate and butyrate) were identical in the samples studied. The composition of the protective medium in which the lyophilized biomaterial corresponds to the original feces in terms of the number of "live" microorganisms has been proposed. According to its physical characteristics lyophilisate is convenient for capsules preparation.

Article Details

How to Cite
Sorokina, E., Zhgun, E., Kislun, Y., Denisova, E., Bespyatykh, Y., & Ilina, E. (2021). Optimization of Conditions for Human Bacterial Preparation for Biological Correction of Intestinal Microflora. Biomedical Chemistry: Research and Methods, 4(2), e00151. https://doi.org/10.18097/BMCRM00151
Issue
Vol. 4 No. 2 (2021)
Section
EXPERIMENTAL RESEARCH

References

  1. Lin, Z., Iqbal, Z., Ortiz, J.F., Khan, S.A., Jahan, N. (2020) Fecal Microbiota Transplantation in Recurrent Clostridium Difficile Infection: Is it Superior to Other Conventional Methods? Cureus. 12(8), e9653. DOI
  2. Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies (2013) Retrieved from: www.fda.gov
  3. Smith, M., Kassam, Z., Edelstein, C., Burgess, J., Alm, E. (2014). OpenBiome remains open to serve the medical community. Nat. Biotechnol., 32, 867. DOI
  4. Tan, P., Li, X., Shen, J., Feng, Q. (2020). Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease: An Update. Front Pharmacol. 11, 574533. DOI
  5. Taur, Y., Coyte, K., Schluter, J., Robilotti, E., Figueroa, C., Gjonbalaj, M., Littmann, E.R., Ling, L., Miller, L., Gyaltshen, Y., Fontana, E., Morjaria, S., Gyurkocza, B., Perales, M.A., Castro-Malaspina, H., Tamari, R., Ponce, D., Koehne, G., Barker, J., Jakubowski, A., Papadopoulos, E., Dahi, P., Sauter, C., Shaffer, B., Young, J.W., Peled, J., Meagher, R.C., Jenq, R.R., van den Brink, M.R.M., Giralt, S.A., Pame,r E.G., Xavier, J.B. (2018) Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant. Sci Transl Med. 10(460), eaap9489. DOI
  6. Kang, D-W., Adams, J.B., Gregory, A.C., Borody, T., Chittick, L., Fasano, A., Khoruts, A., Geis, E., Maldonado, J., McDonough-Means, S., Pollard, E.L., Roux, S., Sadowsky, M.J., Schwarzberg Lipson, K., Sullivan, M.B., Caporaso, G.J. Krajmalnik-Brown, R. (2017). Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome, 5(1), 10. DOI
  7. Evrensel, A., Ceylan, M.E. (2011). Fecal Microbiota Transplantation and Its Usage in Neuropsychiatric Disorders. Clin. Phychopharmacol. Neurosci., 14(3), 231-237. DOI
  8. Jiang, Z.D., Ajami, N.J., Petrosino, J.F., Jun, G., Hanis, C.L., Shah, M., Hochman, L., Ankoma-Sey, V., DuPont, A.W., Wong, M.C., Alexander, A., Ke, S., DuPont, H.L. (2017). Randomised clinical trial: faecal microbiota transplantation for recurrent Clostridum difficile infection - fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy. Aliment Pharmacol Ther. 45(7), 899-908 . DOI
  9. Lee, C.H., Steiner, T., Petrof, E.O., Smieja, M., Roscoe, D., Nematallah, A., Weese, J.S., Collins, S., Moayyedi, P., Crowther, M., Ropeleski, M.J., Jayaratne, P., Higgins, D., Li, Y., Rau, N.V., Kim, P.T. (2016). Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial. JAMA. 315(2), 142-9. DOI
  10. Costello, S.P., Conlon, M.A., Vuaran, M.S., Roberts-Thomson, I.C., Andrews, J.M. (2015). Faecal microbiota transplant for recurrent Clostridium difficile infection using long-term frozen stool is effective: clinical efficacy and bacterial viability data. Aliment Pharmacol Ther. 42(8), 1011-8. DOI
  11. Staley, C., Hamilton, M.J., Vaughn, B.P., Graiziger, C.T., Newman, K.M., Kabage, A.J., Sadowsky, M.J., Khoruts, A. (2017). Successful Resolution of Recurrent Clostridium difficile Infection using Freeze-Dried, Encapsulated Fecal Microbiota; Pragmatic Cohort Study. Am J Gastroenterol. 112(6), 940-947. DOI
  12. Kao, D., Roach, B., Silva, M., Beck, P., Rioux, K., Kaplan, G.G., Chang, H.J., Coward, S., Goodman, K.J., Xu, H., Madsen, K., Mason, A., Wong, G.K., Jovel, J., Patterson, J., Louie, T. (2017). Effect of Oral Capsule- vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile Infection: A Randomized Clinical Trial. JAMA. 318(20). 1985-1993. DOI
  13. Zipursky, J.S., Sidorsky, T.I., Freedman, C.A., Sidorsky, M.N., Kirkland, K.B. (2012). Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection. Clin Infect Dis. 5(12). 1652-8. DOI
  14. Peiren, J., Buyse, J., De Vos, P., Lang, E., Clermont, D., Hamon, S., Bégaud, E., Bizet, C., Pascual, J., Ruvira, M.A., Macián, M.C., Arahal, D.R. (2015). Improving survival and storage stability of bacteria recalcitrant to freeze-drying: a coordinated study by European culture collections. Arahal. Appl. Microbiol. Biotechnol. 99(8), 3559–71. DOI
  15. Cabri guidelines. Laboratory procedures of microorganisms. Protective suspension media for freezing or (freeze)-drying. Retrieved November 26, 2020 from: http://www.cabri.org/guidelines/microorganisms/M300Ap3.html.
  16. Schwab C., Vogel R., Ganzle M.G. (2007). Influence of oligosaccharides on the viability and membrane properties of Lactobacillus reuteri TMW1.106 during freeze-drying. Cryobiology. 55(2), 108–14. DOI
  17. Tymczyszyn, E.E., Díaz, M.R., Gómez-Zavaglia, A., Disalvo, E.A. (2007). Volume recovery, surface properties and membrane integrity of Lactobacillus delbrueckii subsp. bulgaricus dehydrated in the presence of trehalose or sucrose. J. Appl. Microbiol. 103(6), 2410–9. DOI
  18. Pehkonen, K.S., Roos, Y.H., Miao, S., Ross, R.P., Stanton, C. (2008). State transitions and physicochemical aspects of cryoprotection and stabilization in freeze-drying of Lactobacillus rhamnosus GG (LGG). J. Appl. Microbiol. 104, 1732–1743. DOI
  19. Zhgun, E.S., Kislun, Y.V., Kalachniuk, T.N., Veselovsky, V.A., Urban, A.S., Tikhonova, P.O., Pavlenko, A.V., Ilchenko, G.N., Ilina, E.N. (2020). Evaluation of the Levels of Metabolites in Feces of Patients with Inflammatory Bowel Diseases. Biomeditsinskaya Khimiya, 66(3), 233–240. DOI
  20. Isolauri, E. (2001). Probiotics in human disease. Am J Clin Nutr. 73(suppl), 1142S–6S. DOI
  21. Gracheva, I.V., Osin, A.V. (2016). Mechanisms of Damaging Bacteria during Lyophilization and Protective Activity of Shielding Media. Problemy Osobo Opasnykh Infektsii. 3(5), 12. DOI
  22. Cummings, J.H., Pomare, E.W., Branch, W.J., Naylor, C.P., Macfarlane, G.T. (1987). Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut, 28(10), 1221-1227. DOI